{"schema_version":"secwatch.filing_event.v1","accession":"0001193125-23-084515","form_type":"8-K","ticker":"XOMA","cik":"0000791908","company_name":"XOMA Royalty Corp","filed_at":"2023-03-30T23:59:59+00:00","discovered_at":"2026-05-14T18:03:48.098600+00:00","generated_at":"2026-06-17T09:53:00.843249+00:00","sec_items":["1.01"],"event_type":"other_material","sentiment":"neutral","materiality_score":0.5,"calibrated_materiality_score":0.5,"confidence":"high","headline":"XOMA acquires IXINITY royalty and milestone payments from Aptevo for $9.6M","bullets":["XOMA (US) LLC paid $9.6M to Aptevo for 100% of deferred payments on IXINITY net sales, plus partial milestone payments.","IXINITY is a hemophilia B treatment marketed by Medexus; purchased receivables stem from a 2020 Aptevo-Medexus sale agreement.","Additional $50k payment to Aptevo if XOMA receives >$500k of Q1 2023 deferred payments from IXINITY.","Agreement includes customary covenants, representations, and indemnification provisions."],"urls":{"canonical":"https://secwatch.observer/filing/0001193125-23-084515","json":"https://secwatch.observer/filing/0001193125-23-084515.json","markdown":"https://secwatch.observer/filing/0001193125-23-084515.md","text":"https://secwatch.observer/filing/0001193125-23-084515.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/791908/000119312523084515/0001193125-23-084515-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/791908/000119312523084515/d477933d8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-17T09:53:00.843249+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"8b0d89674553fdcdea092cc7763050e40e2fcd95","claim":"XOMA Royalty Corp entered into Payment Interest Purchase Agreement with Aptevo Therapeutics Inc. valued at $9.6 million (effective 2023-03-29).","evidence_excerpt":"On March 29, 2023, XOMA (US) LLC (“XOMA”), a wholly-owned subsidiary of XOMA Corporation (the “Company”), entered into a Payment Interest Purchase Agreement (the “Agreement”) with Aptevo Therapeutics Inc., a Delaware corporation (“Aptevo”).","evidence_source":"SEC 8-K Item 1.01/1.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/791908/000119312523084515/0001193125-23-084515-index.htm","confidence":0.9,"family_label":"Material Agreements","details":[{"label":"Action","value":"entry"},{"label":"Agreement","value":"asset purchase"},{"label":"Counterparty","value":"Aptevo Therapeutics Inc."},{"label":"Value","value":"$9.6 million"},{"label":"Effective","value":"2023-03-29"}],"fact_type":"material_agreement"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}